The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of telotristat etiprate on clinical and biochemical responses in patients with symptomatic carcinoid syndrome: Preliminary results of an ongoing phase II, multicenter, open-label, serial-ascending dose study.
Bertram Wiedenmann
Consultant or Advisory Role - Lexicon Pharmaceuticals
Marianne E. Pavel
Consultant or Advisory Role - Lexicon Pharmaceuticals
Thomas Seufferlein
No relevant relationships to disclose
Joel Freiman
Employment or Leadership Position - Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals
Linda Law
Employment or Leadership Position - Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Phillip Lee Banks
Employment or Leadership Position - Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals
Kenneth Frazier
Employment or Leadership Position - Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals
Jessica Jackson
Employment or Leadership Position - Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals
Brian Zambrowicz
Employment or Leadership Position - Lexicon Pharmaceuticals
Stock Ownership - Lexicon Pharmaceuticals